NYSE:MNK Mallinckrodt (MNK) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MNK Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.1350-Day Range$0.14▼$0.7552-Week Range$0.75▼$6.42Volume39,227 shsAverage Volume2.62 million shsMarket Capitalization$1.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipSocial Media Get Mallinckrodt alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Mallinckrodt Stock (NYSE:MNK)Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" MNK Stock News HeadlinesApril 25, 2024 | reuters.comBankruptcy allowed Mallinckrodt to end Acthar royalties, 3rd Circ. rulesApril 14, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces 2024 Extracorporeal Immunomodulation AwardApril 25, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…March 26, 2024 | finance.yahoo.comMallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 GuidanceMarch 4, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 4, 2024 | finance.yahoo.comMallinckrodt Announces Appointment of Paul O'Neill as Executive Vice President, Quality & Operations, Specialty BrandsMarch 1, 2024 | markets.businessinsider.comMallinckrodt Says FDA Grants SNDA For Acthar Gel Single-Dose Pre-Filled SelfJect InjectorFebruary 24, 2024 | benzinga.comMallinckrodt Stock (OTC:MCKPF) Dividends: History, Yield and DatesApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 21, 2024 | finanznachrichten.deMallinckrodt plc: Mallinckrodt Presents Data on Real-World Outcomes with THERAKOS CELLEX Photopheresis System Treatment at the 2024 Tandem MeetingsFebruary 3, 2024 | msn.comMallinckrodt Announces Executive Appointments and Incentive PlansJanuary 31, 2024 | morningstar.comMallinckrodt PLC Ordinary Shares - NewJanuary 9, 2024 | msn.comMallinckrodt to discontinue StrataGraft due to slow uptakeDecember 27, 2023 | finance.yahoo.comMallinckrodt Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality IndexDecember 7, 2023 | sg.finance.yahoo.comMallinckrodt Announces FDA Clearance of the INOmax® EVOLVE™ DS Delivery System and Approval of the INOmax® (nitric oxide) Mini-CylinderDecember 1, 2023 | msn.comMallinckrodt Avoids $40 Million SEC Fine in Medicaid Overcharge CaseNovember 16, 2023 | finance.yahoo.comMallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial ResultsNovember 15, 2023 | msn.comMallinckrodt emerges from bankruptcyNovember 14, 2023 | finance.yahoo.comMallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11October 11, 2023 | msn.comMallinckrodt sees emerging from Chapter 11 by end of yearOctober 11, 2023 | msn.comMallinckrodt Bankruptcy Plan Gets Approval, Will Wipe Out $1 Billion in Opioid PaymentsOctober 11, 2023 | finance.yahoo.comMallinckrodt Approved to End Bankruptcy, Reduce Opioid PaymentsOctober 10, 2023 | reuters.comMallinckrodt gets court approval for restructuring, $1 bln cut to opioid settlementOctober 10, 2023 | finance.yahoo.comMallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring PlanSeptember 20, 2023 | msn.comFirm Retention Summary: MallinckrodtSeptember 20, 2023 | msn.comDrug giant Mallinckrodt enters second Irish ExaminershipSeptember 19, 2023 | msn.comBankrupt Drugmaker Mallinckrodt Considers Sale of Opioid BusinessSee More Headlines Receive MNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/04/2020Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MNK CUSIPN/A CIK1567892 Webwww.mallinckrodt.com Phone(531) 696-0000FaxN/AEmployees2,700Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($116.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net Margins-82.59% Pretax MarginN/A Return on Equity20.32% Return on Assets2.49% Debt Debt-to-Equity Ratio1.18 Current Ratio0.57 Quick Ratio0.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$47.48 per share Price / Book0.00Miscellaneous Outstanding Shares13,170,000Free Float13,131,000Market Cap$1.58 million OptionableNot Optionable BetaN/A Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMark C. TrudeauPresident, Chief Executive Officer & DirectorBryan M. ReasonsChief Financial Officer & Executive Vice PresidentSteven Joseph RomanoChief Scientific Officer & Executive VPBabatunde Adekunle OtulanaChief Medical Officer & Senior Vice PresidentMichele RobertsonChief Compliance Officer & Senior Vice PresidentKey CompetitorsNeuBase TherapeuticsNASDAQ:NBSE180 Life SciencesNASDAQ:ATNFInMed PharmaceuticalsNASDAQ:INMHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLAView All Competitors MNK Stock Analysis - Frequently Asked Questions How were Mallinckrodt's earnings last quarter? Mallinckrodt plc (NYSE:MNK) announced its quarterly earnings data on Tuesday, August, 4th. The company reported $1.89 EPS for the quarter, beating analysts' consensus estimates of $1.34 by $0.55. The firm had revenue of $700.90 million for the quarter, compared to the consensus estimate of $630.19 million. Mallinckrodt had a negative net margin of 82.59% and a positive trailing twelve-month return on equity of 20.32%. The firm's revenue was down 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.53 earnings per share. Read the conference call transcript. What other stocks do shareholders of Mallinckrodt own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD), Micron Technology (MU), Bausch Health Companies (BHC), Endo International (ENDP), Teva Pharmaceutical Industries (TEVA), Gerdau (GGB), AT&T (T), Alibaba Group (BABA), Advanced Micro Devices (AMD). This page (NYSE:MNK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mallinckrodt plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
